Nwam LLC Buys 1,576 Shares of Amgen Inc. $AMGN

Nwam LLC grew its stake in Amgen Inc. (NASDAQ:AMGN) by 11.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,940 shares of the medical research company’s stock after buying an additional 1,576 shares during the quarter. Nwam LLC’s holdings in Amgen were worth $4,718,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in AMGN. Wealth Quarterback LLC boosted its holdings in Amgen by 1.6% in the 3rd quarter. Wealth Quarterback LLC now owns 2,210 shares of the medical research company’s stock worth $624,000 after buying an additional 34 shares during the period. Fairvoy Private Wealth LLC lifted its position in shares of Amgen by 1.1% in the second quarter. Fairvoy Private Wealth LLC now owns 3,171 shares of the medical research company’s stock valued at $885,000 after acquiring an additional 35 shares in the last quarter. Nicholson Wealth Management Group LLC boosted its stake in shares of Amgen by 0.6% in the second quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company’s stock worth $1,652,000 after acquiring an additional 35 shares during the period. LS Investment Advisors LLC grew its position in shares of Amgen by 4.1% during the third quarter. LS Investment Advisors LLC now owns 885 shares of the medical research company’s stock worth $250,000 after purchasing an additional 35 shares in the last quarter. Finally, Crown Wealth Group LLC raised its stake in Amgen by 4.0% during the 3rd quarter. Crown Wealth Group LLC now owns 910 shares of the medical research company’s stock valued at $257,000 after purchasing an additional 35 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently commented on AMGN. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. Royal Bank Of Canada raised their price target on Amgen from $330.00 to $335.00 and gave the stock an “outperform” rating in a research report on Thursday, January 8th. Citigroup boosted their target price on Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a research report on Wednesday, September 24th. Argus raised their price target on shares of Amgen from $310.00 to $360.00 and gave the stock a “buy” rating in a research note on Tuesday, December 30th. Finally, Cantor Fitzgerald lifted their target price on Amgen from $305.00 to $315.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Amgen has a consensus rating of “Moderate Buy” and a consensus price target of $339.45.

Insider Activity at Amgen

In related news, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the sale, the senior vice president owned 7,082 shares in the company, valued at $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the transaction, the senior vice president directly owned 7,225 shares of the company’s stock, valued at $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 10,908 shares of company stock worth $3,674,966 over the last quarter. Insiders own 0.76% of the company’s stock.

Amgen Trading Up 0.3%

NASDAQ AMGN opened at $330.03 on Friday. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $346.38. The company has a fifty day simple moving average of $331.36 and a two-hundred day simple moving average of $305.66. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45. The stock has a market cap of $177.71 billion, a P/E ratio of 25.50, a P/E/G ratio of 2.93 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.01 by $0.63. The firm had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The firm’s revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the firm earned $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be paid a $2.52 dividend. The ex-dividend date is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. Amgen’s dividend payout ratio (DPR) is 73.57%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.